Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, McGregor IS, Wiley JL, Thomas BF.

J Pharmacol Exp Ther. 2018 May;365(2):437-446. doi: 10.1124/jpet.117.246983. Epub 2018 Mar 16.

PMID:
29549157
2.

Labeling Accuracy of Cannabidiol Extracts Sold Online.

Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R.

JAMA. 2017 Nov 7;318(17):1708-1709. doi: 10.1001/jama.2017.11909. No abstract available.

3.

Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.

Marusich JA, Wiley JL, Lefever TW, Patel PR, Thomas BF.

Neuropharmacology. 2017 Nov 4. pii: S0028-3908(17)30508-7. doi: 10.1016/j.neuropharm.2017.10.041. [Epub ahead of print]

PMID:
29113898
4.

Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Gamage TF, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Drug Test Anal. 2018 Jan;10(1):137-147. doi: 10.1002/dta.2262. Epub 2017 Sep 28.

PMID:
28834241
5.

In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Forensic Toxicol. 2017;35(2):333-347. doi: 10.1007/s11419-017-0361-1. Epub 2017 Mar 10.

6.

The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators.

Gamage TF, Farquhar CE, Lefever TW, Thomas BF, Nguyen T, Zhang Y, Wiley JL.

Neuropharmacology. 2017 Oct;125:365-375. doi: 10.1016/j.neuropharm.2017.08.008. Epub 2017 Aug 10.

PMID:
28803965
7.

Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.

Nguyen T, German N, Decker AM, Langston TL, Gamage TF, Farquhar CE, Li JX, Wiley JL, Thomas BF, Zhang Y.

J Med Chem. 2017 Sep 14;60(17):7410-7424. doi: 10.1021/acs.jmedchem.7b00707. Epub 2017 Aug 18.

PMID:
28792219
8.

Interactions of Cannabinoids With Biochemical Substrates.

Thomas BF.

Subst Abuse. 2017 May 29;11:1178221817711418. doi: 10.1177/1178221817711418. eCollection 2017. Review.

9.

Identification of Eight Synthetic Cannabinoids, Including 5F-AKB48 in Seized Herbal Products Using DART-TOF-MS and LC-QTOF-MS as Nontargeted Screening Methods.

Moore KN, Garvin D, Thomas BF, Grabenauer M.

J Forensic Sci. 2017 Sep;62(5):1151-1158. doi: 10.1111/1556-4029.13367. Epub 2017 Jun 9.

PMID:
28597943
10.

Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice.

Lefever TW, Marusich JA, Thomas BF, Barrus DG, Peiper NC, Kevin RC, Wiley JL.

Subst Abuse. 2017 Apr 7;11:1178221817701739. doi: 10.1177/1178221817701739. eCollection 2017.

11.

Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model.

Grim TW, Morales AJ, Thomas BF, Wiley JL, Endres GW, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2017 Jul;362(1):210-218. doi: 10.1124/jpet.117.240192. Epub 2017 Apr 25.

PMID:
28442584
12.

Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Lefever TW, Lee YO, Kovach AL, Silinski MA, Marusich JA, Thomas BF, Wiley JL.

Drug Alcohol Depend. 2017 Mar 1;172:80-87. doi: 10.1016/j.drugalcdep.2016.12.004. Epub 2017 Jan 18.

13.

Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Thomas BF, Lefever TW, Cortes RA, Grabenauer M, Kovach AL, Cox AO, Patel PR, Pollard GT, Marusich JA, Kevin RC, Gamage TF, Wiley JL.

J Pharmacol Exp Ther. 2017 Apr;361(1):162-171. doi: 10.1124/jpet.116.238717. Epub 2017 Jan 13. Erratum in: J Pharmacol Exp Ther. 2017 May;361(2):245.

14.

Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.

Nguyen T, Li JX, Thomas BF, Wiley JL, Kenakin TP, Zhang Y.

Med Res Rev. 2017 May;37(3):441-474. doi: 10.1002/med.21418. Epub 2016 Nov 23. Review.

15.

Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.

Grim TW, Morales AJ, Gonek MM, Wiley JL, Thomas BF, Endres GW, Sim-Selley LJ, Selley DE, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2016 Nov;359(2):329-339. Epub 2016 Aug 17.

16.

Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.

Wiley JL, Marusich JA, Thomas BF.

Curr Top Behav Neurosci. 2017;32:231-248. doi: 10.1007/7854_2016_17. Review.

PMID:
27753007
17.

Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States.

Thomas BF, Pollard GT.

Front Pharmacol. 2016 Aug 31;7:285. doi: 10.3389/fphar.2016.00285. eCollection 2016.

18.

Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.

Seltzman HH, Shiner C, Hirt EE, Gilliam AF, Thomas BF, Maitra R, Snyder R, Black SL, Patel PR, Mulpuri Y, Spigelman I.

J Med Chem. 2016 Aug 25;59(16):7525-43. doi: 10.1021/acs.jmedchem.6b00516. Epub 2016 Aug 10.

19.

Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Wiley JL, Lefever TW, Marusich JA, Grabenauer M, Moore KN, Huffman JW, Thomas BF.

Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.

20.

Medullary Endocannabinoids Contribute to the Differential Resting Baroreflex Sensitivity in Rats with Altered Brain Renin-Angiotensin System Expression.

Schaich CL, Grabenauer M, Thomas BF, Shaltout HA, Gallagher PE, Howlett AC, Diz DI.

Front Physiol. 2016 Jun 9;7:207. doi: 10.3389/fphys.2016.00207. eCollection 2016.

21.

Pharmacological effects of methamphetamine and alpha-PVP vapor and injection.

Marusich JA, Lefever TW, Blough BE, Thomas BF, Wiley JL.

Neurotoxicology. 2016 Jul;55:83-91. doi: 10.1016/j.neuro.2016.05.015. Epub 2016 May 26.

22.

Quantifying renewable groundwater stress with GRACE.

Richey AS, Thomas BF, Lo MH, Reager JT, Famiglietti JS, Voss K, Swenson S, Rodell M.

Water Resour Res. 2015 Jul;51(7):5217-5238. Epub 2015 Jul 14.

23.

Uncertainty in global groundwater storage estimates in a Total Groundwater Stress framework.

Richey AS, Thomas BF, Lo MH, Famiglietti JS, Swenson S, Rodell M.

Water Resour Res. 2015 Jul;51(7):5198-5216. Epub 2015 Jul 14.

24.

The importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.

Perrey DA, Decker AM, Li JX, Gilmour BP, Thomas BF, Harris DL, Runyon SP, Zhang Y.

Bioorg Med Chem. 2015 Sep 1;23(17):5709-24. doi: 10.1016/j.bmc.2015.07.013. Epub 2015 Jul 16.

25.

AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.

Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, Patel PR, Grabenauer M, Moore KN, Thomas BF.

J Pharmacol Exp Ther. 2015 Sep;354(3):328-39. doi: 10.1124/jpet.115.225326. Epub 2015 Jun 23.

26.

Groundwater depletion during drought threatens future water security of the Colorado River Basin.

Castle SL, Thomas BF, Reager JT, Rodell M, Swenson SC, Famiglietti JS.

Geophys Res Lett. 2014 Aug 28;41(16):5904-5911. Epub 2014 Aug 29.

27.

Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators.

Nguyen T, German N, Decker AM, Li JX, Wiley JL, Thomas BF, Kenakin TP, Zhang Y.

Bioorg Med Chem. 2015 May 1;23(9):2195-2203. doi: 10.1016/j.bmc.2015.02.058. Epub 2015 Mar 7.

28.

Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Perrey DA, German NA, Decker AM, Thorn D, Li JX, Gilmour BP, Thomas BF, Harris DL, Runyon SP, Zhang Y.

ACS Chem Neurosci. 2015 Apr 15;6(4):599-614. doi: 10.1021/cn500330v. Epub 2015 Feb 12.

29.

Alterations in the Medullary Endocannabinoid System Contribute to Age-related Impairment of Baroreflex Sensitivity.

Schaich CL, Shaltout HA, Grabenauer M, Thomas BF, Gallagher PE, Howlett AC, Diz DI.

J Cardiovasc Pharmacol. 2015 May;65(5):473-9. doi: 10.1097/FJC.0000000000000216.

30.

Determination of behaviorally effective tobacco constituent doses in rats.

Wiley JL, Marusich JA, Thomas BF, Jackson KJ.

Nicotine Tob Res. 2015 Mar;17(3):368-71. doi: 10.1093/ntr/ntu194. Epub 2014 Sep 30.

31.

Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).

German N, Decker AM, Gilmour BP, Gay EA, Wiley JL, Thomas BF, Zhang Y.

J Med Chem. 2014 Sep 25;57(18):7758-69. doi: 10.1021/jm501042u. Epub 2014 Sep 4.

32.

Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers.

Perrey DA, Gilmour BP, Thomas BF, Zhang Y.

ACS Med Chem Lett. 2014 Mar 25;5(6):634-8. doi: 10.1021/ml4004759. eCollection 2014 Jun 12.

33.

Truncated Orexin Peptides: Structure-Activity Relationship Studies.

German NA, Decker AM, Gilmour BP, Thomas BF, Zhang Y.

ACS Med Chem Lett. 2013 Dec 12;4(12):1224-1227.

34.

Acute and chronic effects of a contraceptive compound RTI-4587-073(l) on testicular histology and endocrine function in miniature horse stallions.

Pozor MA, Zambrano G, Roser J, Hess R, Runyon S, Runcan E, Thomas BF, Dymock D, Macpherson ML, Troedsson MH, Kelleman A.

Reprod Domest Anim. 2014 Jun;49(3):392-402. doi: 10.1111/rda.12286. Epub 2014 Mar 5.

PMID:
24593030
35.

Indenopyride derivative RTI-4587-073(l): a candidate for male contraception in stallions.

Pozor MA, Macpherson ML, McDonnell SM, Nollin M, Roser JF, Love C, Runyon S, Thomas BF, Troedsson MH.

Theriogenology. 2013 Dec;80(9):1006-16. doi: 10.1016/j.theriogenology.2013.07.029. Epub 2013 Aug 30.

PMID:
23998737
36.

Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.

Perrey DA, German NA, Gilmour BP, Li JX, Harris DL, Thomas BF, Zhang Y.

J Med Chem. 2013 Sep 12;56(17):6901-16. doi: 10.1021/jm400720h. Epub 2013 Aug 26.

37.

Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Moore KN, Thomas BF.

Neuropharmacology. 2013 Dec;75:145-54. doi: 10.1016/j.neuropharm.2013.07.022. Epub 2013 Aug 2.

38.

The importance of hydrogen bonding and aromatic stacking to the affinity and efficacy of cannabinoid receptor CB2 antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide (SR144528).

Kotsikorou E, Navas F 3rd, Roche MJ, Gilliam AF, Thomas BF, Seltzman HH, Kumar P, Song ZH, Hurst DP, Lynch DL, Reggio PH.

J Med Chem. 2013 Sep 12;56(17):6593-612. doi: 10.1021/jm400070u. Epub 2013 Aug 14.

39.

Dose-response effects of spectrum research cigarettes.

Hatsukami DK, Heishman SJ, Vogel RI, Denlinger RL, Roper-Batker AN, Mackowick KM, Jensen J, Murphy SE, Thomas BF, Donny E.

Nicotine Tob Res. 2013 Jun;15(6):1113-21. doi: 10.1093/ntr/nts247. Epub 2012 Nov 22.

40.

Analytical surveillance of emerging drugs of abuse and drug formulations.

Thomas BF, Pollard GT, Grabenauer M.

Life Sci. 2013 Mar 19;92(8-9):512-9. doi: 10.1016/j.lfs.2012.10.031. Epub 2012 Nov 12. Review.

41.

Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice.

Wiley JL, Marusich JA, Zhang Y, Fulp A, Maitra R, Thomas BF, Mahadevan A.

Eur J Pharmacol. 2012 Nov 15;695(1-3):62-70. doi: 10.1016/j.ejphar.2012.08.019. Epub 2012 Sep 6.

42.

Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-c]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping.

Murineddu G, Asproni B, Ruiu S, Deligia F, Falzoi M, Pau A, Thomas BF, Zhang Y, Pinna GA, Pani L, Lazzari P.

Open Med Chem J. 2012;6:1-14. doi: 10.2174/1874104501206010001. Epub 2012 May 17.

43.

Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV).

Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, Olive MF.

Addict Biol. 2014 Mar;19(2):165-74. doi: 10.1111/j.1369-1600.2012.00474.x. Epub 2012 Jul 11.

44.

Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs.

Grabenauer M, Krol WL, Wiley JL, Thomas BF.

Anal Chem. 2012 Jul 3;84(13):5574-81. doi: 10.1021/ac300509h. Epub 2012 Jun 20.

45.

Use of SPME-HS-GC-MS for the analysis of herbal products containing synthetic cannabinoids.

Cox AO, Daw RC, Mason MD, Grabenauer M, Pande PG, Davis KH, Wiley JL, Stout PR, Thomas BF, Huffman JW.

J Anal Toxicol. 2012 Jun;36(5):293-302. doi: 10.1093/jat/bks025.

46.

Hijacking of Basic Research: The Case of Synthetic Cannabinoids.

Wiley JL, Marusich JA, Huffman JW, Balster RL, Thomas BF.

Methods Rep RTI Press. 2011 Nov;2011. pii: 17971.

47.

Diaryl urea analogues of SB-334867 as orexin-1 receptor antagonists.

Perrey DA, Gilmour BP, Runyon SP, Thomas BF, Zhang Y.

Bioorg Med Chem Lett. 2011 May 15;21(10):2980-5. doi: 10.1016/j.bmcl.2011.03.048. Epub 2011 Mar 21.

48.

Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.

Zhang Y, Gilliam A, Maitra R, Damaj MI, Tajuba JM, Seltzman HH, Thomas BF.

J Med Chem. 2010 Oct 14;53(19):7048-60. doi: 10.1021/jm1006676.

49.

Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.

Walentiny DM, Vann RE, Warner JA, King LS, Seltzman HH, Navarro HA, Twine CE Jr, Thomas BF, Gilliam AF, Gilmour BP, Carroll FI, Wiley JL.

Psychopharmacology (Berl). 2010 Jun;210(2):275-84. doi: 10.1007/s00213-010-1827-6. Epub 2010 Mar 31.

50.

Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes.

Lindeblad MO, Bauer KS, Zakharov AD, Hill JM, Green JS, Thomas BF, Schwartz A, Kapetanovic IM, Lyubimov A.

Chem Biol Interact. 2010 Jan 27;183(2):317-26. doi: 10.1016/j.cbi.2009.10.004. Epub 2009 Dec 6.

PMID:
19836365

Supplemental Content

Loading ...
Support Center